Last Updated : November 21, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Alecensaro | Alectinib | Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Alecensaro | Alectinib | Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
Alecensaro | alectinib | ALK-positive NSCLC | Reimburse with clinical criteria and/or conditions | Active | ||
Alimta | Pemetrexed | Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Aloxi (capsule) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list | Complete | ||
Aloxi (capsule) | Palonosetron | Chemotherapy-induced nausea and vomiting | Withdrawn | |||
Aloxi (injection) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list at the submitted price | Complete | ||
Alsitek | masitinib mesylate | Amyotrophic lateral sclerosis (ALS) | Suspended | |||
Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | Cancelled | |||
Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | List | Complete | ||
Altace Plus Felodipine | Ramipril/felodipine extended release | Hypertension | Do not list | Complete | ||
Alunbrig | Brigatinib | NSCLC | Do not reimburse | Complete | ||
Alunbrig | Brigatinib | (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Alvesco | Ciclesonide | asthma | List | Complete | ||
Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
Amvuttra | vutrisiran | Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) | Reimburse with clinical criteria and/or conditions | Complete | ||
Anoro Ellipta | Umeclidinium/vilanterol | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | ||
Apidra | Insulin glulisine | Diabetes, Mellitus (Type 1 & 2) | List in a similar manner to other drugs in class | Complete | ||
Apprilon | Doxycycline monohydrate | Rosacea | Do not list | Complete | ||
Apretude | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Reimburse with clinical criteria and/or conditions | Active | ||
Aptiom | Eslicarbazepine acetate | Epilepsy, partial-onset seizures | List with criteria/condition | Complete | ||
Aptivus | Tipranavir | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Arbesda RespiClick | fluticasone propionate / salmeterol xinafoate | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
Arnuity Ellipta | Fluticasone furoate | Asthma | List with criteria/condition | Complete |